| Bioactivity | Bliretrigine is a sodium channel blocker. Bliretrigine has the effect of relieving pain[1][2][3]. | ||||||||||||
| Name | Bliretrigine | ||||||||||||
| CAS | 1233229-75-8 | ||||||||||||
| Formula | C20H24N4O2 | ||||||||||||
| Molar Mass | 352.43 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022. [2]. Yoshihiro OYAMADA, et al. External medicinal preparation containing N2-{[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl}-L-alanineamide for treating and/or preventing peripheral neuropathic pain. Patent AU2019306705. [3]. Hironori Kinoshita, et al. Preparation of N2-[(benzimidazol-2-yl or imidazo[4,5-b]pyridin-2-yl)methyl]amino acid amide derivatives as inhibitors of sensory neuron specific sodium channel (SNS). Patent AU2009331179. |